Q-omics provides the consensus-scored NAALADL1 profile across patient tissues and cancer cell-line models. NAALADL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NAALADL1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, NAALADL1 RNA expression shows 17,522 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where NAALADL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAALADL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAALADL1 survival associations across molecular data types. NAALADL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAALADL1 RNA expression–survival associations across cancer types. High NAALADL1 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SARC, LUAD, CHOL and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NAALADL1 RNA expression.
This table summarizes NAALADL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NAALADL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAALADL1 shows lower tumor expression in COAD, KICH, BLCA, LUSC, LUAD and UCEC. The COAD box plot shows higher NAALADL1 RNA expression in normal versus tumor tissue (log2 FC = −2.588, t-test p < 0.001).
This table shows molecular features associated with NAALADL1 in patient tissues and cancer cell lines. In patient samples, NAALADL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAALADL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
